Hemoglobin Switching Meeting

血红蛋白转换会议

基本信息

批准号：
10064453
负责人：
LEONARD Ira ZON
金额：
$ 1万
依托单位：
BOSTON CHILDREN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10064453
关键词：
American Society of Hematology Anabolism Back Biochemical Biochemistry Carbon Dioxide Cell Differentiation process Cells Cellular biology Clinical Collaborations Complementary DNA Crete Development Developmental Biology Disease Epigenetic Process Erythrocytes Erythropoietin Etiology Europe Faculty Family Fertilization Gene Expression Regulation Genes Genetic Genetic Diseases Genomics Globin Greece Hematology Hematopoietic Hemoglobin Hemoglobinopathies Hereditary Disease Human Cloning Human Genetics Inherited International Lung Metabolic Diseases Metabolism Minority Molecular Molecular Biology Mutation Oxygen Participant Physiology Postdoctoral Fellow Process Research Research Personnel Science Scientist Sickle Cell Anemia Site Structure Students Therapeutic Clinical Trial Tissues Woman Work beta Thalassemia career disease phenotype drug development effective therapy gene therapy genomic locus man meetings novel phenomenological models stem cells success symposium therapy development transcription factor

项目摘要

Abstract The biennial Hemoglobin Switching Conferences have been ongoing for 43 years, and there are multiple reasons for its resounding, continued success. First and foremost, the organizers Higgs, Engel, Zon and Sankaran strive to identify and then highlight new discoveries by always including new, young investigators and studies that impinge on the process of globin biosynthesis. Second, this is the only venue (other than the annual ASH meeting, with more than 25,000 participants) that brings together basic scientists and clinicians to discuss both the molecular and developmental origins of, and treatments for, the hemoglobinopathies, the most common inherited diseases in man. Third, the meetings have historically evolved with intense focus on wherever the science led, thus remaining extremely topical, and has not only been the forum for presenting the first cDNA clones, the first cloned human genomic locus (and the first mutations in same), the structure of erythropoietin and the discovery of the GATA and KLF transcription factor families, but it has also launched the careers of many of the current leaders in this field (indeed, numerous former postdoctoral fellows and current faculty first presented their work in plenary sessions at this conference). Fourth, this is the only meeting on this topic that routinely has approximately equal attendance by investigators from both inside and outside the U.S., and this fact is reflected by the biennial alternation in conference site between the U.S. and Europe. In 2020 the Conference will be held in Crete, Greece.

抽象的两年一度的血红蛋白转换会议已举办了 43 年，有多个其持续取得巨大成功的原因。首先也是最重要的，组织者希格斯、恩格尔、佐恩和桑卡兰致力于识别并突出新发现，始终邀请新的年轻研究人员参与以及影响珠蛋白生物合成过程的研究。其次，这是唯一的场地（除了年度 ASH 会议，有超过 25,000 名参与者），汇集了基础科学家和临床医生讨论血红蛋白病的分子和发育起源以及治疗方法，人类最常见的遗传性疾病。第三，从历史上看，会议的发展重点是无论科学引领何处，因此仍然极具话题性，并且不仅是展示科学的论坛第一个 cDNA 克隆、第一个克隆的人类基因组位点（以及其中的第一个突变）、促红细胞生成素以及 GATA 和 KLF 转录因子家族的发现，但它还推出了该领域许多现任领导者的职业生涯（事实上，许多前博士后研究员和现任教师们首先在本次会议的全体会议上介绍了他们的工作）。第四，这是唯一一次关于此问题的会议来自美国国内外的调查人员通常出席率大致相同的主题，美国和欧洲每两年更换一次会议地点就反映了这一事实。 2020年会议将在希腊克里特岛举行。